Story perspectives

Oruka’s Injectable Clears 63% Psoriasis, Near Blockbuster Levels

4/28/2026

Summary

Story summary

Oruka Therapeutics reported that its long-acting injectable ORKA-001 cleared the skin of 63% of plaque-psoriasis patients in a mid-stage trial.
The results suggest ORKA-001 could achieve remission rates equal to or greater than the current blockbusters Skyrizi and Bimzelx.
An updated blood-exposure analysis supports the potential for ORKA-001 to be administered only once per year.
Oruka still must conduct late-stage clinical trials before the drug can receive approval.

1 of 1

Story summary

Oruka Therapeutics reported that its long-acting injectable ORKA-001 cleared the skin of 63% of plaque-psoriasis patients in a mid-stage trial.
The results suggest ORKA-001 could achieve remission rates equal to or greater than the current blockbusters Skyrizi and Bimzelx.
An updated blood-exposure analysis supports the potential for ORKA-001 to be administered only once per year.
Oruka still must conduct late-stage clinical trials before the drug can receive approval.